Finnhub · Apr 28, 2026
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from S&P Global BMI Index
Amicus Therapeutics, Inc. dropped from S&P Global BMI Index...
NASDAQ · FOLD
Amicus Therapeutics, Inc.
Healthcare · Biotechnology
$14.49
Up+$0.00 (+0.00%)
Updated Oct 7, 2026, 10:06 PM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.05B
- P/E ratio
- 153.57
- Dividend yield
- 0.00%
- 52-week range
- $5.51 – $14.50
- Volume
- 5.29M
- Avg. volume
- 5.17M
Price performance · FOLD
FOLD price history
1M range · 0 trading sessions · Daily adjusted prices
FOLD does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest FOLD news
The latest Smart Investors Daily articles mentioning FOLD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
FOLD research
Overview
Company profile and research snapshot.
Company profile
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 22, 2026 | Jefferies | Hold | — |
| Dec 29, 2025 | Leerink Partners | Market Perform | — |
| Dec 22, 2025 | Citigroup | Neutral | — |
| Dec 19, 2025 | Needham | Hold | — |
| Dec 19, 2025 | Cantor Fitzgerald | Neutral | — |
News briefing
No generated briefing is available yet.
Finnhub · Apr 28, 2026
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from S&P TMI Index
Amicus Therapeutics, Inc. dropped from S&P TMI Index...
Finnhub · Apr 28, 2026
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from S&P Biotechnology Select Industry Index
Amicus Therapeutics, Inc. dropped from S&P Biotechnology Select Industry Index...
SeekingAlpha · Apr 28, 2026
SBIO: Leaning Into Drug Discovery And Medical Breakthroughs
Discover ALPS Medical Breakthroughs ETF (SBIO): late-stage biotech picks targeting FDA approvals & M&A.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
